Market Place
Sourcing Support
Ultimovacs ASA: Approval and publication of prospectus
28 Feb 2025 //
GLOBENEWSWIRE
Ultimovacs ASA: Cancellation of subsequent repair offering
13 Feb 2025 //
GLOBENEWSWIRE
Ultimovacs ASA Reports Q4 2024 Financial Results & Update
31 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to Q4 2024 results webcast presentation
27 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs ASA Extraordinary General Meeting held on Jan 9, 2025
09 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs ASA: Notification of major holdings
09 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs ASA Announces Voting Rights Of Extraordinary Meeting
08 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs Discloses Voting Rights Of Extraordinary General Meeting
06 Jan 2025 //
GLOBENEWSWIRE
Regarding the extraordinary general meeting on 9 January 2025
05 Jan 2025 //
GLOBENEWSWIRE
Ultimovacs: Notice of extraordinary general meeting on 9 Jan 2024
19 Dec 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Extraordinary General Meeting on 9 Jan 2024
19 Dec 2024 //
GLOBENEWSWIRE
ULTI – EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY
18 Dec 2024 //
GLOBENEWSWIRE
Ultimovas Announces Business Merger with Zelluna Immunotherapy
17 Dec 2024 //
GLOBENEWSWIRE
Ultimovacs ASA Mandatory notification of trade
17 Dec 2024 //
GLOBENEWSWIRE
Ultimovacs ASA Announces Potential Subsequent Repair Offering
17 Dec 2024 //
GLOBENEWSWIRE
Ultimovacs ASA Reports Q3 2024 Results & Business Update
06 Nov 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to Q3 2024 results webcast presentation
31 Oct 2024 //
GLOBENEWSWIRE
Ultimovacs Publishes Phase II FOCUS Trial Results on medRxiv
25 Oct 2024 //
GLOBENEWSWIRE
Ultimovacs Halts Patient Recruitment In LUNGVAC Trial For Lung Cancer
11 Sep 2024 //
GLOBENEWSWIRE
Ultimovacs Updates On UV1 Phase II NIPU Trial At ESMO 2024
08 Sep 2024 //
GLOBENEWSWIRE
Ultimovacs Reports Q2 2024 Results And Provides Business Update
21 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation
15 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs Announces Notice of Resignation from Deputy Board Member
07 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs Announces FOCUS Phase II Trial Results For UV1
05 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs Cancer Vaccine Fails Third Trial
05 Aug 2024 //
FIERCE BIOTECH
Ultimovacs To Present NIPU Trial Update At ESMO Congress 2024
01 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs ASA announces revised terms of the employee share option program
24 Jun 2024 //
GLOBENEWSWIRE
Ultimovacs provides update from Phase I study in malignant melanoma
11 Jun 2024 //
GLOBENEWSWIRE
Ultimovacs Poster On UV1 Cancer Vaccine At 2024 ASCO Annual Meeting
01 Jun 2024 //
GLOBENEWSWIRE
Ultimovacs Q1 2024 Results And Business Update
07 May 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
30 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs to Present Poster at ASCO 2024 Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs ASA “ Annual General Meeting held on April 18, 2024
18 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs lays off 40% in wake of cancer vaccine`s phase 2 fail
17 Apr 2024 //
FIERCE BIOTECH
Ultimovacs Adjusts Operations to Advance UV1 Vaccine Phase II Program
16 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs AGM Voting Rights Disclosure
15 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs“ Invitation to Business Update on April 17, 2024
09 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs to Present Poster at the AACR Annual Meeting 2024
04 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
25 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Annual Report 2023
21 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Mandatory notification of trades by primary insider
09 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Mandatory notification of trades by primary insider
08 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs Announces Results from INITIUM Study Evaluating UV1 Vaccination
07 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Mandatory notification of trade by primary insiders
07 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs announces publication of results from NIPU Phase II trial with UV1
02 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine
19 Feb 2024 //
GLOBENEWSWIRE
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results
14 Feb 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
08 Feb 2024 //
GLOBENEWSWIRE
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine
05 Feb 2024 //
GLOBENEWSWIRE
Ultimovacs Updates Timeline for Reporting on UV1 Phase II Trial INITIUM
16 Jan 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Mandatory notification of trade by primary insider
04 Jan 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Mandatory notification of trade by primary insider
02 Jan 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Mandatory notification of trade by primary insider
19 Dec 2023 //
GLOBENEWSWIRE
Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
28 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs ASA: Share capital increase related to exercise of options
09 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs ASA Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs ASA: Mandatory notification of trade by primary insider
08 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs Announces Completion of Patient Enrollment in Study to INITIUM
02 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation
02 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs Announces Protocol Amendment in UV1 PII Study in Malignant Melanoma
31 Oct 2023 //
GLOBENEWSWIRE
